ETV1-Positive Cells Give Rise to BRAFV600E -Mutant Gastrointestinal Stromal Tumors.

Gastrointestinal stromal tumor (GIST) is the most common subtype of sarcoma. Despite clinical advances in the treatment of KIT/PDGFRA-mutant GIST, similar progress against KIT/PDGFRA wild-type GIST, including mutant BRAF-driven tumors, has been limited by a lack of model systems. ETV1 is a master regulator in the intestinal cells of Cajal (ICC), thought to be the cells of origin of GIST. Here, we present a model in which the ETV1 promoter is used to specifically and inducibly drive Cre recombinase in ICC as a strategy to study GIST pathogenesis. Using a conditional allele for BrafV600E , a mutation observed in clinical cases of GIST, we observed that BrafV600E activation was sufficient to drive ICC hyperplasia but not GIST tumorigenesis. In contrast, combining BrafV600E activation with Trp53 loss was sufficient to drive both ICC hyperplasia and formation of multifocal GIST-like tumors in the mouse gastrointestinal tract with 100% penetrance. This mouse model of sporadic GIST model was amenable to therapeutic intervention, and it recapitulated clinical responses to RAF inhibition seen in human GIST. Our work offers a useful in vivo model of human sporadic forms of BRAF-mutant GIST to help unravel its pathogenesis and therapeutic response to novel experimental agents. Cancer Res; 77(14); 3758-65. ©2017 AACR.

[1]  A. Hartmann,et al.  Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors. , 2016, American journal of clinical pathology.

[2]  P. Meltzer,et al.  Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. , 2016, JAMA oncology.

[3]  Ke-er Huang,et al.  KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance , 2015, Gastric Cancer.

[4]  C. Antonescu,et al.  Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. , 2015, Cancer discovery.

[5]  Staci A. Sorensen,et al.  Anatomical characterization of Cre driver mice for neural circuit mapping and manipulation , 2014, Front. Neural Circuits.

[6]  R. Kurzrock,et al.  BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance , 2013, Oncotarget.

[7]  A. Hauschild,et al.  Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[8]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[9]  J. Kirkwood,et al.  Targeted therapies: BREAKing a path for progress—dabrafenib confirms class effect , 2012, Nature Reviews Clinical Oncology.

[10]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[11]  C. Antonescu,et al.  Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor , 2012, Proceedings of the National Academy of Sciences.

[12]  J. Fletcher,et al.  p53 Modulation as a Therapeutic Strategy in Gastrointestinal Stromal Tumors , 2012, PloS one.

[13]  M. Heinrich,et al.  Gastrointestinal stromal tumours: origin and molecular oncology , 2011, Nature Reviews Cancer.

[14]  S. Nelson,et al.  A Resource of Cre Driver Lines for Genetic Targeting of GABAergic Neurons in Cerebral Cortex , 2011, Neuron.

[15]  Eric C. Sorenson,et al.  Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido , 2012 .

[16]  C. Antonescu,et al.  ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours , 2010, Nature.

[17]  B. Rubin,et al.  Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. , 2010, Gastroenterology.

[18]  C. Antonescu,et al.  Imatinib Upregulates Compensatory Integrin Signaling in a Mouse Model of Gastrointestinal Stromal Tumor and Is More Effective When Combined with Dasatinib , 2010, Molecular Cancer Research.

[19]  Allan R. Jones,et al.  A robust and high-throughput Cre reporting and characterization system for the whole mouse brain , 2009, Nature Neuroscience.

[20]  A. Hartmann,et al.  V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours , 2009, Journal of Clinical Pathology.

[21]  S. Ward,et al.  Changes in the structure and function of ICC networks in ICC hyperplasia and gastrointestinal stromal tumors. , 2009, Gastroenterology.

[22]  Narasimhan P. Agaram,et al.  Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors , 2008, Genes, chromosomes & cancer.

[23]  S. Hirota,et al.  A mouse model of a human multiple GIST family with KIT‐Asp820Tyr mutation generated by a knock‐in strategy , 2008, The Journal of pathology.

[24]  M. Heinrich,et al.  Molecular pathobiology of gastrointestinal stromal sarcomas. , 2008, Annual review of pathology.

[25]  M. Serrano,et al.  A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. , 2007, Genes & development.

[26]  N. Socci,et al.  Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor , 2006, Proceedings of the National Academy of Sciences.

[27]  C. Antonescu,et al.  A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. , 2005, Cancer research.

[28]  B. Nilsson,et al.  Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era , 2005, Cancer.

[29]  C. Antonescu,et al.  Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[31]  Jean-Yves Scoazec,et al.  BRAF mutation status in gastrointestinal stromal tumors. , 2010, American journal of clinical pathology.